Affimed NV(AFMD)stock report

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

Market Cap:191.3M; Shares Outstanding:76.2M; Short Interest: 5.85%; Q2 2019(6/30/19): Cash:no data. Loss 11.63M

EPS and Sales:


Date Sales % last year % last quarter
2018.6.30 0.77M -24.81% -65.93%
2018.12.31 26.7M 1080.85% 3367.53%
2019.3.31 12.77M 2034.02% -52.17%
2019.6.30 17.28M 2152.35% 35.32%


Insider Transactions:

Institution Ownership:

Total institutions: 99,no change
Shares hold: 31256.2k shares. no change
shares% hold: 41.99%,no change

Analyst Ratings:

This Post Has One Comment

  1. Wan Joy
    Wan Joy

    looks like Wellington increased their position with approx 1mm more shares.

Leave a Reply